NCT07171203View on ClinicalTrials.gov

Neoadjuvant Imatinib and Fampridine in KIT Mutant Gastrointestinal Stromal Tumor

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

December 31, 2025

Primary Completion Date

July 31, 2030

Study Completion Date

July 31, 2031

Conditions
Gastrointestinal Stromal Tumors
Interventions
DRUG

Imatinib

Tyrosine kinase inhibitor. Imatinib will be dosed at 400 mg once a day. Dose can be reduced by 100 mg per dose reduction step if clinically indicated.

DRUG

Fampridine

Voltage-gated potassium channel (VGKC) blocker. Fampridine will be dosed in a 3+3 design at 10 mg given either every 2 days, or every day, or twice a day.

Trial Locations (1)

92093

University of California, San Diego, La Jolla

All Listed Sponsors
lead

University of California, San Diego

OTHER